Roivant Sciences Ltd (NASDAQ: ROIV) on Tuesday, plunged -0.32% from the previous trading day, before settling in for the closing price of $21.7. Within the past 52 weeks, ROIV’s price has moved between $8.73 and $23.47.
Healthcare Sector giant saw their annual sales slid by -99.51% over the last five years. The company achieved an average annual earnings per share of -365.48%. With a float of $437.46 million, this company’s outstanding shares have now reached $689.70 million.
Roivant Sciences Ltd (ROIV) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Roivant Sciences Ltd is 37.10%, while institutional ownership is 63.51%. The most recent insider transaction that took place on Dec 23 ’25, was worth 9,122,307. In this transaction CFO of this company sold 406,731 shares at a rate of $22.43, taking the stock ownership to the 239,413 shares. Before that another transaction happened on Dec 23 ’25, when Company’s President & Immunovant CEO sold 200,000 for $22.45, making the entire transaction worth $4,490,000. This insider now owns 1,611,749 shares in total.
Roivant Sciences Ltd (ROIV) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.2 earnings per share (EPS) for the period topping the consensus outlook (set at -0.24) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -365.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -25.94% during the next five years compared to -99.51% drop over the previous five years of trading.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Roivant Sciences Ltd (ROIV) is currently performing well based on its current performance indicators. A quick ratio of 33.70 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 739.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.26 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Analysing the last 5-days average volume posted by the [Roivant Sciences Ltd, ROIV], we can find that recorded value of 4.96 million was lower than the volume posted last year of 6.65 million. As of the previous 9 days, the stock’s Stochastic %D was 16.56%.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 85.36%, which indicates a significant increase from 44.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.80 in the past 14 days, which was higher than the 0.56 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.57, while its 200-day Moving Average is $14.11. Now, the first resistance to watch is $21.86. This is followed by the second major resistance level at $22.09. The third major resistance level sits at $22.34. If the price goes on to break the first support level at $21.38, it is likely to go to the next support level at $21.13. Now, if the price goes above the second support level, the third support stands at $20.90.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
Market capitalization of the company is 15.04 billion based on 695,492K outstanding shares. Right now, sales total 29,050 K and income totals -171,980 K. The company made 1,570 K in profit during its latest quarter, and -113,520 K in sales during its previous quarter.
